TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29969138

Group type: EXPERIMENTAL
Intervention: Nurse-Supported Advance Care Planning (NSACP) intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 50
Study: 27344823

Group type: EXPERIMENTAL
Intervention: He's fire needle therapy applied for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 50
Study: 24660971

Group type: EXPERIMENTAL
Intervention: Activity groups
Number of subjects: 277

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 277
Study: 22420830

Group type: EXPERIMENTAL
Intervention: 0.06 mg.kg(‐1) rocuronium priming followed by 0.54 mg.kg(‐1) rocuronium
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 50 mg.kg(‐1) magnesium sulphate
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combination of magnesium sulphate and rocuronium priming
Number of subjects: 92

Group type: COMPARATOR
Intervention: 0.6 mg.kg(‐1) rocuronium
Number of subjects: 92
Study: 20107199

Group type: EXPERIMENTAL
Intervention: Tomato juice containing 90 mmol Na (B)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tomato juice containing 140 mmol Na (C)
Number of subjects: 35
Study: 17660483

Group type: EXPERIMENTAL
Intervention: Oral roflumilast 500 mug, once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Concomitant administration of roflumilast and budesonide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Roflumilast AUC and C(max)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Roflumilast N‐oxide and budesonide AUC and C(max)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Coadministration of roflumilast and budesonide
Number of subjects: 12
Study: 15465743

Group type: EXPERIMENTAL
Intervention: Soygerm (1.1 micromol/kg body weight)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Novasoy isoflavone extract (1.5 micromol/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fermented soygerm (3.3 micromol/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Low daidzein degradation phenotype
Number of subjects: 25
Study: 11408982

Group type: EXPERIMENTAL
Intervention: Dalteparin 200 units/kg given subcutaneously on the two mornings prior to the procedure and restarted 12-24 hours after the procedure until INR was therapeutic.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 24
Study: 9589648

Group type: EXPERIMENTAL
Intervention: Miglitol 25 mg TID
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Miglitol 50 mg TID
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Glyburide (titrated dose)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo TID
Number of subjects: 411
Study: 7978718

Group type: EXPERIMENTAL
Intervention: Oral estradiol 1 mg/d
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral estradiol 2 mg/d
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 2521816

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (cilazapril)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31393029

Group type: EXPERIMENTAL
Intervention: MI‐SI plus treatment as usual (TAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MI‐SI‐R plus treatment as usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 0
Study: 31676505

Group type: EXPERIMENTAL
Intervention: Crisis Intervention Team (CIT) model
Number of subjects: 0
Study: 29768332

Group type: EXPERIMENTAL
Intervention: Customized arch support insoles for 12 weeks
Number of subjects: 52
Study: 27299675

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg or 25 mg once daily)
Number of subjects: 6185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6185
Study: 25110374

Group type: EXPERIMENTAL
Intervention: Three rounds of azithromycin mass drug administration (MDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: One round of azithromycin mass drug administration (MDA)
Number of subjects: 0
Study: 22468770

Group type: EXPERIMENTAL
Intervention: Surrogate Decision Making Confidence Scale
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Values of Life‐Sustaining Treatment Outcomes
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Goals of Care documents
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dyad congruence in values for life‐sustaining treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dyad congruence in goals of care
Number of subjects: 58
Study: 20592248

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 297
Study: 17547539

Group type: EXPERIMENTAL
Intervention: DHA group (BSF plus fish oil DHA 200 mg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (combined groups not receiving DHA: BS and BSF)
Number of subjects: 144
Study: 16287768

Group type: EXPERIMENTAL
Intervention: Decision-support tool (Couplers)
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1902
Study: 11916809

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 50
Study: 10803133

Group type: EXPERIMENTAL
Intervention: Helioseal F
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fissurit F
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Cotton roll isolation
Number of subjects: 58
Study: 7673021

Group type: EXPERIMENTAL
Intervention: Radiotherapy with bromodeoxyuridine (BrdUrd) 0.8 g/m2 per day for 4 days of each of 3 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Radiotherapy alone (37.5 Gy in 15 fractions of 2.5 Gy)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 72
Study: 2041549

Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside (100 mg intravenously per day for 18 to 32 doses)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (intravenously per day for 18 to 32 doses)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 6102458

Group type: EXPERIMENTAL
Intervention: Butaperazine maleate
Number of subjects: 24
Study: 31784343

Group type: EXPERIMENTAL
Intervention: PrEP (300 mg tenofovir disoproxil fumarate and 200 mg emtricitabine per pill)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 30931709

Group type: EXPERIMENTAL
Intervention: 25% silver nitrate (AgNO3) solution followed by a 5% sodium fluoride (NaF) varnish, semiannually (every 6 months)
Number of subjects: 1070

Group type: COMPARATOR
Intervention: 38% silver diamine fluoride (SDF) solution followed by a placebo varnish, semiannually (every 6 months)
Number of subjects: 1070
Study: 28295217

Group type: EXPERIMENTAL
Intervention: Laparoscopic 270° posterior fundoplication (Toupet)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Laparoscopic 180° anterior fundoplication
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 94
Study: 25976063

Group type: EXPERIMENTAL
Intervention: Carbetocin (100-µg i.v. bolus)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intra-umbilical oxytocin (50 IU in 30 mL saline)
Number of subjects: 78
Study: 25215305

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG) subjects
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Subjects with highest BMI in 2005
Number of subjects: 94
Study: 22272740

Group type: EXPERIMENTAL
Intervention: Schema Therapy (ST)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Clarification Oriented Psychotherapy (COP)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 300
Study: 20810312

Group type: EXPERIMENTAL
Intervention: Modafinil (400mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 17139670

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 9404

Group type: COMPARATOR
Intervention: Femoral access with sheath size 4 or 5 French (Fr)
Number of subjects: 9404

Group type: COMPARATOR
Intervention: Femoral access with sheath size 6 Fr
Number of subjects: 9404

Group type: COMPARATOR
Intervention: Femoral access with sheath size 7 Fr
Number of subjects: 9404

Group type: COMPARATOR
Intervention: Femoral access with sheath size >or=8 Fr
Number of subjects: 9404

Group type: EXPERIMENTAL
Intervention: Larger sheath size and delayed sheath removal
Number of subjects: 9404
Study: 15942511

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (2 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Oral dexamethasone (0.15 mg/kg)
Number of subjects: 72
Study: 12198600

Group type: EXPERIMENTAL
Intervention: Large-volume liposuction
Number of subjects: 12
Study: 9787368

Group type: EXPERIMENTAL
Intervention: Dorzolamide-timolol combination (2.0% dorzolamide and 0.5% timolol) administered twice daily
Number of subjects: 335

Group type: COMPARATOR
Intervention: 2.0% dorzolamide administered three times daily
Number of subjects: 335

Group type: COMPARATOR
Intervention: 0.5% timolol administered twice daily
Number of subjects: 335
Study: 7882126

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise (PFM)
Number of subjects: 23
Study: 2297102

Group type: EXPERIMENTAL
Intervention: General anesthesia (thiopental-nitrous oxide-halothane)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (0.5% bupivacaine)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: General anesthesia with local anesthesia (infiltration of the abdominal wall with 0.25% bupivacaine)
Number of subjects: 36

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: General anesthesia plus local anesthesia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 36
Study: 7392427

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Immune complexes (detected by Clq-binding and Raji cell assays)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Presence of immune complexes
Number of subjects: 96
Study: 31968400

Group type: EXPERIMENTAL
Intervention: Allen Carr's Easyway (ACE)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Specialist stop smoking service (SSS)
Number of subjects: 620
Study: 29943822

Group type: EXPERIMENTAL
Intervention: Self-sampling (SS arm) using the Rover VIBA-brush
Number of subjects: 19523

Group type: COMPARATOR
Intervention: Assisted sampling (AS arm) using the cytobrush
Number of subjects: 19523

Group type: EXPERIMENTAL
Intervention: Self-sampling (SS arm)
Number of subjects: 19523

Group type: COMPARATOR
Intervention: Assisted sampling (AS arm)
Number of subjects: 19523
Study: 27600055

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) 843 mg of (−)-epigallocatechin-3-gallate (EGCG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) with high COMT genotype
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 60
Study: 25869561

Group type: EXPERIMENTAL
Intervention: Fasudil (Rho kinase inhibitor)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 80
Study: 24481886

Group type: EXPERIMENTAL
Intervention: Trauma-Focused Early Intensive Cognitive Behavioral Intervention (TF-EICBI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No intervention (NEIG)
Number of subjects: 21
Study: 17972445

Group type: EXPERIMENTAL
Intervention: Dentifrice with triclosan (n=28)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional dentifrice (n=29)
Number of subjects: 57
Study: 15266215

Group type: EXPERIMENTAL
Intervention: Valdecoxib (10-80 mg daily)
Number of subjects: 7934

Group type: EXPERIMENTAL
Intervention: Nonselective NSAIDs (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid)
Number of subjects: 7934

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7934

Group type: EXPERIMENTAL
Intervention: Users of aspirin
Number of subjects: 7934

Group type: EXPERIMENTAL
Intervention: Valdecoxib (therapeutic doses 10 or 20 mg daily and supratherapeutic doses 40 or 80 mg daily)
Number of subjects: 7934
Study: 10781642

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Atorvastatin (5 mg/day)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 8833557

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention including diabetes education, medication counseling, dietary regulation, exercise, home blood glucose monitoring, and hypoglycemic regimen adjustment.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard medical care provided by physicians (Control group).
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pharmacist intervention vs Control group.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pharmacist intervention and Control group.
Number of subjects: 39
Study: 1388954

Group type: EXPERIMENTAL
Intervention: Cavit base
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IRM base
Number of subjects: 45

Group type: COMPARATOR
Intervention: No base
Number of subjects: 45
Study: 3886357

Group type: EXPERIMENTAL
Intervention: Felodipine 5mg three times daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nifedipine 10mg three times daily
Number of subjects: 18
Study: 31702056

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg in 2 mL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg in 2 mL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90
Study: 30137218

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Weight Stability (WS)
Number of subjects: 95
Study: 27884765

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg, Naproxen 200 mg, Oseltamivir 75 mg twice daily for 2 days, followed by Oseltamivir 75 mg twice daily for 3 days
Number of subjects: 217

Group type: COMPARATOR
Intervention: Oseltamivir 75 mg twice daily for 5 days (control)
Number of subjects: 217
Study: 25881884

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 167

Group type: COMPARATOR
Intervention: White Light Imaging
Number of subjects: 167
Study: 23901667

Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No episiotomy (group 2)
Number of subjects: 100
Study: 21367948

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet (<20 g/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calorie-restricted diet (1200-1500 kcal/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both interventions (carbohydrate and calorie restriction)
Number of subjects: 18
Study: 19761358

Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS) 0.8 U/kg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Insulin glargine (G) 0.8 U/kg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Insulin detemir (D) 0.8 U/kg
Number of subjects: 34
Study: 17045796

Group type: COMPARATOR
Intervention: Continuous tamoxifen (40 mg daily)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Intermittent tamoxifen
Number of subjects: 276

Group type: COMPARATOR
Intervention: Intermittent/alternated tamoxifen and medroxyprogesterone acetate (MPA, 300 mg daily)
Number of subjects: 276
Study: 14751652

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 32
Study: 10902257

Group type: EXPERIMENTAL
Intervention: Serological testing for Bordetella pertussis
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Culture confirmation of pertussis
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Incidence of pertussis
Number of subjects: 356

Group type: COMPARATOR
Intervention: Statutory notifications of pertussis
Number of subjects: 356
Study: 9324165

Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK8; 12.5 pmol/kg x h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Yolk intake
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA; 4.0 micromol/kg x h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L‐arginine (1 mmol/kg x h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 8453706

Group type: EXPERIMENTAL
Intervention: Ifosfamide (3,750 mg/m2 on days 1 and 2 every 3 weeks) + Doxorubicin (30 mg/m2 for 2 days)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Doxorubicin (80 mg/m2 every 3 weeks)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Doxorubicin (40 mg/m2) + Mitomycin (8 mg/m2) + Cisplatin (60 mg/m2, all given intravenously on day 1)
Number of subjects: 260
Study: 2420444

Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: ADM‐Reg (doxorubicin-containing regimen)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: ADM‐Reg (MABOP)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: ADM‐Reg (ABVD)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: ADM‐Reg (MOPP alternated with ABVD)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: ADM‐Reg
Number of subjects: 122

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: MABOP
Number of subjects: 122
Study: 31899723

Group type: EXPERIMENTAL
Intervention: Suprainguinal FICB with 30 mL of 0.375% ropivacaine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Infrainguinal FICB with 30 mL of 0.375% ropivacaine
Number of subjects: 74
Study: 30536353

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25529756

Group type: EXPERIMENTAL
Intervention: 150 mg day-1 ranitidine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 300 mg day-1 ranitidine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Olanzapine only (control)
Number of subjects: 75
Study: 24571704

Group type: EXPERIMENTAL
Intervention: Stabilised, stannous fluoride (SnF2) dentifrice (1,100 ppm F as SnF2 + 350 ppm F as NaF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sodium fluoride (NaF) dentifrice (1,450 ppm F as NaF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 12
Study: 22847287

Group type: EXPERIMENTAL
Intervention: Sweet potato/footbath/acupressure massage (SFA) intervention combined with usual care
Number of subjects: 93
Study: 20226474

Group type: EXPERIMENTAL
Intervention: Cryobiopsy
Number of subjects: 296

Group type: COMPARATOR
Intervention: Forceps biopsy
Number of subjects: 296
Study: 18400123

Group type: EXPERIMENTAL
Intervention: Multidisciplinary fall prevention program
Number of subjects: 333

Group type: COMPARATOR
Intervention: Usual Dutch healthcare (control)
Number of subjects: 333
Study: 16398970

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 100
Study: 12771323

Group type: EXPERIMENTAL
Intervention: Refined olive oil (rich in monounsaturated fatty acids, n = 17)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rapeseed oil (rich in MUFA and alpha‐linolenic acid, n = 13)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sunflower oil (rich in (n‐6) PUFA, n = 18)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Baseline diet rich in saturated fatty acids
Number of subjects: 48
Study: 10470628

Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sevoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sevoflurane with nitrous oxide (N2O)
Number of subjects: 30
Study: 8544269

Group type: EXPERIMENTAL
Intervention: GG167 (3.6 to 16 mg, administered intranasally two or six times daily)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: GG167 (early treatment)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: GG167 (other measures)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: GG167 (twice daily dosing)
Number of subjects: 166
Study: 1704089

Group type: EXPERIMENTAL
Intervention: Subcutaneous hydromorphone infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous hydromorphone infusion
Number of subjects: 15
Study: 6884415

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 300 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Phenylbutazone (various doses: 90 mg, 150 mg, 180 mg, 240 mg, 270 mg, 300 mg, 360 mg, 450 mg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Phenylbutazone
Number of subjects: 32
Study: 30362211

Group type: EXPERIMENTAL
Intervention: Suprapubic pressure (SuPuP) applied during hysteroscopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: No suprapubic pressure (control group)
Number of subjects: 60
Study: 29273659

Group type: EXPERIMENTAL
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Open microdiscectomy
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: PTED
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Economic evaluation from a societal perspective
Number of subjects: 682
Study: 25651447

Group type: EXPERIMENTAL
Intervention: Volunteer assistance during lunch meals
Number of subjects: 8

Group type: COMPARATOR
Intervention: Days without volunteer assistance
Number of subjects: 8
Study: 25448497

Group type: EXPERIMENTAL
Intervention: Combined treatment of atorvastatin calcium and methylprednisolone
Number of subjects: 38
Study: 21733697

Group type: EXPERIMENTAL
Intervention: 10mg/kg tranexamic acid at induction of anaesthesia
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 10 ml of fibrin spray administered topically during surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group receiving neither treatment
Number of subjects: 66
Study: 19268281

Group type: EXPERIMENTAL
Intervention: Acceptance-based treatment for tinnitus distress
Number of subjects: 19
Study: 18019049

Group type: EXPERIMENTAL
Intervention: Observational studies and pragmatic trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional RCTs
Number of subjects: 0